BioArctic AB - ESG Rating & Company Profile powered by AI
If you work at BioArctic AB and you would like to licence your Sustainability rating, please get in touch. Check the end of this page for potential risks for BioArctic AB based on industry, geography and size. The analysis of BioArctic AB employs data points from across the internet and also from available filings by BioArctic AB.
BioArctic AB in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 6.8; made up of an environmental score of 6.0, social score of 8.0 and governance score of 6.4.
6.8
Medium ImpactEnvironmental
Social
Governance
Peer Group Comparison
| Rank | Company | SDG Transparency Score ⓘ | Performance |
|---|---|---|---|
| 1 | Caladrius Biosciences Inc | 8.0 | High |
| 1 | Can Fite Biopharma Ltd | 8.0 | High |
| 294 | SMS Pharmaceuticals Ltd | 6.9 | High |
| 294 | Takeda Pharmaceutical Co Ltd | 6.9 | High |
| 314 | BioArctic AB | 6.8 | High |
| 314 | Camurus AB | 6.8 | High |
| 314 | Cassiopea SpA | 6.8 | High |
| ... | ... | ... | |
| 1970 | Zyden Gentec Ltd | 0.0 | Low |
| 1970 | iNtRON Biotechnology Inc | 0.0 | Low |
| ... | ... | ... |
Frequently Asked Questions
Does BioArctic AB have an accelerator or VC vehicle to help deliver innovation?
Sign up for free to unlockDoes BioArctic AB disclose current and historical energy intensity?
Sign up for free to unlockDoes BioArctic AB report the average age of the workforce?
Sign up for free to unlockDoes BioArctic AB reference operational or capital allocation in relation to climate change?
Sign up for free to unlockDoes BioArctic AB disclose its ethnicity pay gap?
Sign up for free to unlockDoes BioArctic AB disclose cybersecurity risks?
Sign up for free to unlockDoes BioArctic AB offer flexible work?
Sign up for free to unlockDoes BioArctic AB have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Sign up for free to unlockDoes BioArctic AB disclose the number of employees in R&D functions?
Sign up for free to unlockDoes BioArctic AB conduct supply chain audits?
Sign up for free to unlockDoes BioArctic AB disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Sign up for free to unlockIs there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Sign up for free to unlockDoes BioArctic AB conduct 360 degree staff reviews?
Sign up for free to unlockDoes BioArctic AB disclose the individual responsible for D&I?
Sign up for free to unlockDoes BioArctic AB disclose current and historical air emissions?
Sign up for free to unlockIs there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Sign up for free to unlockIs executive remuneration linked to climate performance?
Sign up for free to unlockDoes the Board describe its role in the oversight of climate-related risks and opportunities?
Sign up for free to unlockDoes BioArctic AB disclose current and / or historical scope 2 emissions?
Sign up for free to unlockDoes BioArctic AB disclose water use targets?
Sign up for free to unlockDoes BioArctic AB have careers partnerships with academic institutions?
Sign up for free to unlockDid BioArctic AB have a product recall in the last two years?
Sign up for free to unlockDoes BioArctic AB disclose incidents of discrimination?
Sign up for free to unlockDoes BioArctic AB allow for Work Councils/Collective Agreements to be formed?
Sign up for free to unlockHas BioArctic AB issued a profit warning in the past 24 months?
Sign up for free to unlockDoes BioArctic AB disclose parental leave metrics?
Sign up for free to unlockDoes BioArctic AB disclose climate scenario or pathway analysis?
Sign up for free to unlockDoes BioArctic AB disclose current and / or historical scope 1 emissions?
Sign up for free to unlockAre Operating Expesnses linked to emissions reduction?
Sign up for free to unlockDoes BioArctic AB disclose the pay ratio of women to men?
Sign up for free to unlockDoes BioArctic AB support suppliers with sustainability related research and development?
Sign up for free to unlockDoes BioArctic AB disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Sign up for free to unlockDoes BioArctic AB reflect climate-related risks in its financial statements?
Sign up for free to unlockIs there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Sign up for free to unlockIs BioArctic AB involved in embryonic stem cell research?
Sign up for free to unlockDoes BioArctic AB disclose GHG and Air Emissions intensity?
Sign up for free to unlockDoes BioArctic AB disclose its waste policy?
Sign up for free to unlockDoes BioArctic AB report according to TCFD requirements?
Sign up for free to unlockDoes BioArctic AB disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Sign up for free to unlockDoes BioArctic AB disclose energy use targets?
Sign up for free to unlockDoes BioArctic AB disclose its Renewable Energy targets?
Subscription requiredAre emissions metrics verified by STBi?
Subscription requiredDoes BioArctic AB have a policy relating to cyber security?
Sign up for free to unlockHave a different question?
Potential Risks for BioArctic AB
These potential risks are based on the size, segment and geographies of the company.
BioArctic AB (publ), a research-intensive biopharmaceutical company, develops biological drugs for patients with neurodegenerative disorders in Sweden. The company develops BAN2401, an immunotherapy, which is in Phase III clinical trials targeting the toxic amyloid-beta oligomers/protofibrils in Alzheimer's disease; and is in preclinical trials for treating Down's syndrome with dementia and traumatic brain injury, as well as BAN2401 Back-up, a disease modifying antibody treatment that is in late preclinical Phase for patients with early Alzheimer's disease. It also develops ABBV-0805, a monoclonal antibody for treating Parkinson's disease; and SC0806, a biodegradable device that is in Phase I/II clinical trial for spinal cord injuries. In addition, the company develops imaging and biochemical biomarkers for Alzheimer's and Parkinson's disease; and blood-brain-barrier technology that enables the passage of antibodies and other substances into the brain through the blood brain barrier, as well as focuses on developing ND3014 antibodies for treating neurodegenerative disorders; AD1801, AD1502, AD1503, AD-BT2802, AD-BT2803, and AD2603 for the treatment of Alzheimer's disease; and PD1601 and PD1602 for the treatment of Parkinson's disease. It has research collaboration agreement with Eisai and AbbVie. The company was formerly known as BioArctic Neuroscience AB and changed its name to BioArctic AB (publ) in 2016. BioArctic AB (publ) was founded in 1992 and is based in Stockholm, Sweden.